Abstract
Introduction: New antipsychotics continuously arrive on the market, which thereby influences the approved and off-label prescribing (OLP) schemes. We aimed to identify the recent trends in the OLP of antipsychotics. We conducted a literature review based on three different populations: adult, pediatric, and elderly patients. Methods: A literature search was performed in the PubMed and ScienceDirect databases using the following keyword algorithm: “offlabel” AND (“antipsychotic*” OR “neuroleptic*”). The period investigated ranged from January 2000 to January 2015. Only Englishwritten pharmacoepidemiological studies were included.
Results: Seventy-seven relevant results were identified. Among adults, OLP consisted of 40 to 75% of all antipsychotic prescriptions. The main indications were mood disorders, anxiety disorders, insomnia and agitation. Quetiapine was the most frequently prescribed offlabel antipsychotic, especially for anxiety and insomnia. Among children, OLP was estimated between 36 and 93.2% of all antipsychotic prescriptions. Risperidone and aripiprazole were primarily used and were most often prescribed for attention deficit hyperactivity disorder, anxiety, or mood disorders. Among elderly individuals, OLP consisted of 22 to 86% of all antipsychotic prescriptions. Antipsychotic OLP was particularly frequent for agitation; however, a recent decrease in this OLP was identified.
Discussion: Antipsychotics have largely been prescribed off-label in recent years. The types of antipsychotic OLP practices differ according to the age category of patients. OLP is often used in cases of therapeutic dead-ends or for specific disorders with few or no currently approved medications. However, other OLP practices only reflect temporary prescription trends for mild symptoms, which may induce safety concerns.
Keywords: Adults, antipsychotics, children, elderly, off-label, pharmacoepidemiology, safety.
Current Pharmaceutical Design
Title:Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Volume: 21 Issue: 23
Author(s): Louise Carton, Olivier Cottencin, Maryse Lapeyre-Mestre, Pierre A. Geoffroy, Jonathan Favre, Nicolas Simon, Regis Bordet and Benjamin Rolland
Affiliation:
Keywords: Adults, antipsychotics, children, elderly, off-label, pharmacoepidemiology, safety.
Abstract: Introduction: New antipsychotics continuously arrive on the market, which thereby influences the approved and off-label prescribing (OLP) schemes. We aimed to identify the recent trends in the OLP of antipsychotics. We conducted a literature review based on three different populations: adult, pediatric, and elderly patients. Methods: A literature search was performed in the PubMed and ScienceDirect databases using the following keyword algorithm: “offlabel” AND (“antipsychotic*” OR “neuroleptic*”). The period investigated ranged from January 2000 to January 2015. Only Englishwritten pharmacoepidemiological studies were included.
Results: Seventy-seven relevant results were identified. Among adults, OLP consisted of 40 to 75% of all antipsychotic prescriptions. The main indications were mood disorders, anxiety disorders, insomnia and agitation. Quetiapine was the most frequently prescribed offlabel antipsychotic, especially for anxiety and insomnia. Among children, OLP was estimated between 36 and 93.2% of all antipsychotic prescriptions. Risperidone and aripiprazole were primarily used and were most often prescribed for attention deficit hyperactivity disorder, anxiety, or mood disorders. Among elderly individuals, OLP consisted of 22 to 86% of all antipsychotic prescriptions. Antipsychotic OLP was particularly frequent for agitation; however, a recent decrease in this OLP was identified.
Discussion: Antipsychotics have largely been prescribed off-label in recent years. The types of antipsychotic OLP practices differ according to the age category of patients. OLP is often used in cases of therapeutic dead-ends or for specific disorders with few or no currently approved medications. However, other OLP practices only reflect temporary prescription trends for mild symptoms, which may induce safety concerns.
Export Options
About this article
Cite this article as:
Carton Louise, Cottencin Olivier, Lapeyre-Mestre Maryse, Geoffroy A. Pierre, Favre Jonathan, Simon Nicolas, Bordet Regis and Rolland Benjamin, Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619092903
DOI https://dx.doi.org/10.2174/1381612821666150619092903 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Diversity of Senile Plaques in Alzheimers Disease as Revealed by a New Monoclonal Antibody that Recognizes an Internal Sequence of the Aβ Peptide
Current Alzheimer Research Editorial Thematic Issue: Targeting Synaptic Dysfunction and Neural Connectivity in Neurological and Psychiatric Disorders
Current Pharmaceutical Design Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Lagenaria siceraria: A Potential Source of Anti-Hyperlipidemic and Other Pharmacological Agents
Current Nutrition & Food Science Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Targeting Functional Biomarkers in Schizophrenia with Neuroimaging
Current Pharmaceutical Design The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Clinical Case of a Combination of Endocrine, Metabolic, and Mental Pathologies: Hypopituitarism Associated with Organic Personality Disorder
New Emirates Medical Journal Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Withdrawal Notice: Neuroprotective Effect of Lithospermum officinale callus Extract on Inflamed Primary Microglial Cells
Current Pharmaceutical Biotechnology The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Current Alzheimer Research Gene Control of Synaptic Plasticity and Memory Formation: Implications for Diseases and Therapeutic Strategies
Current Molecular Medicine Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry